

World Journal of *Hepatology*

World J Hepatol 2024 February 27; 16(2): 112-299



EDITORIAL

- 112 New markers of fibrosis in hepatitis C: A step towards the Holy Grail?
Dabos KJ
- 115 Can rifaximin for hepatic encephalopathy be discontinued during broad-spectrum antibiotic treatment?
Huang CH, Amodio P
- 120 Insights into skullcap herb-induced liver injury
Soldera J
- 123 Non-invasive assessment of esophageal varices: Status of today
Gupta T
- 126 Contemporary concepts of prevention and management of gastroesophageal variceal bleeding in liver cirrhosis patients
Garbuzenko DV
- 135 Advancements in autoimmune hepatitis management: Perspectives for future guidelines
Mucenic M
- 140 Interleukins in liver disease treatment
Yang M, Zhang CY
- 146 Changes in the etiology of liver cirrhosis and the corresponding management strategies
Dai JJ, Liu YY, Zhang ZH

REVIEW

- 152 Metabolic-associated fatty liver disease and sarcopenia: A double whammy
Viswanath A, Fouda S, Fernandez CJ, Pappachan JM
- 164 Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapy
Zhou XQ, Li YP, Dang SS

MINIREVIEWS

- 177 Dynamic changes and clinical value of lipocalin 2 in liver diseases caused by microbial infections
Chen F, Wu SS, Chen C, Zhou C
- 186 Recent advances in the diagnosis of drug-induced liver injury
Ahmed T, Ahmad J

ORIGINAL ARTICLE**Retrospective Cohort Study**

- 193 Predicting major adverse cardiovascular events after orthotopic liver transplantation using a supervised machine learning model: A cohort study

Soldera J, Corso LL, Rech MM, Ballotin VR, Bigarella LG, Tomé F, Moraes N, Balbinot RS, Rodriguez S, Brandão ABM, Hochegger B

- 211 Effects of SARS-CoV-2 infection on incidence and treatment strategies of hepatocellular carcinoma in people with chronic liver disease

Mak LY, Chung MSH, Li X, Lai FTT, Wan EYF, Chui CSL, Cheng FWT, Chan EWY, Cheung CL, Au ICH, Xiong X, Seto WK, Yuen MF, Wong CKH, Wong ICK

Retrospective Study

- 229 Epidemiological survey of cystic echinococcosis in southwest China: From the Qinghai-Tibet plateau to the area of Yunnan

Zi JR, Xiao D, Peng J, Wu FW, Li JX, Yan XL, Wang ZQ, Cai X, Xu Q, Li BF, Yang YM

Observational Study

- 241 Predictors of portal vein thrombosis after splenectomy in patients with cirrhosis

Li T, Wang LL, Li YP, Gan J, Wei XS, Mao XR, Li JF

- 251 Evaluation of G3BP1 in the prognosis of acute and acute-on-chronic liver failure after the treatment of artificial liver support system

Li WY, Wang LW, Dong J, Wang Y

Basic Study

- 264 Yinhuang granule alleviates carbon tetrachloride-induced liver fibrosis in mice and its mechanism

Ouyang H, Miao H, Li Z, Wu D, Gao SC, Dai YY, Gao XD, Chai HS, Hu WY, Zhu JF

CASE REPORT

- 279 Coinfection with hepatic cystic and alveolar echinococcosis with abdominal wall abscess and sinus tract formation: A case report

Wang MM, An XQ, Chai JP, Yang JY, A JD, A XR

- 286 Autoimmune hepatitis and primary sclerosing cholangitis after direct-acting antiviral treatment for hepatitis C virus: A case report

Morihisa Y, Chung H, Towatari S, Yamashita D, Inokuma T

LETTER TO THE EDITOR

- 294 Anti-oxidative stress treatment and current clinical trials

Zhang CY, Yang M

ABOUT COVER

Editorial Board Member of *World Journal of Hepatology*, Nobuyuki Takemura, MD, PhD, FACS, Professor, Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Saitama 350-8550, Japan. takemuranobu-tyk@umin.ac.jp

AIMS AND SCOPE

The primary aim of *World Journal of Hepatology* (*WJH*, *World J Hepatol*) is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING

The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (ESCI), Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJH* as 2.4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yi-Xuan Cai; Production Department Director: Xu Guo; Editorial Office Director: Xiang Li.

NAME OF JOURNAL

World Journal of Hepatology

ISSN

ISSN 1948-5182 (online)

LAUNCH DATE

October 31, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Nikolaos Pyrsopoulos, Ke-Qin Hu, Koo Jeong Kang

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-5182/editorialboard.htm>

PUBLICATION DATE

February 27, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

Shuang-Suo Dang

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER'S OFFICIAL WEBSITE

http://2yuan.xjtu.edu.cn/Html/Departments/Main/Index_21148.html



New markers of fibrosis in hepatitis C: A step towards the Holy Grail?

Konstantinos John Dabos

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Gao S, China; Wang XN, China

Received: November 15, 2023

Peer-review started: November 15, 2023

First decision: December 5, 2023

Revised: December 12, 2023

Accepted: January 12, 2024

Article in press: January 12, 2024

Published online: February 27, 2024



Konstantinos John Dabos, Department of Hepatology, St Hohn's Hospital, Livingston EH54 6PP, West Lothian, United Kingdom

Corresponding author: Konstantinos John Dabos, MD, PhD, Doctor, Department of Hepatology, St Hohn's Hospital, Howden Road West, Livingston EH54 6PP, West Lothian, United Kingdom. konstantinos.dabos@nhslothian.scot.nhs.uk

Abstract

In the present issue of the *World Journal of Hepatology*, Ferrassi *et al* examine the problem of liver fibrosis staging in chronic hepatitis C. They identify novel biomarkers in an effort to predict accurate fibrosis staging with the aid of the metabolome of Hepatitis C patients. Overall I think Ferrassi *et al* took a different approach in identifying fibrosis biomarkers, by looking at the patients' metabolome. Their biomarkers clearly separate patients from controls. They can also separate out, patients with minimal fibrosis (F0-F1 stage) and patients with cirrhosis (F4 stage). Obviously, if these biomarkers were to be widely used, tests for all the important metabolites would need to be readily available for use in hospitals or outpatient setting and that may prove difficult and above all, costly. Nevertheless, this step could eventually lead to a metabolomic approach for novel biomarkers of Fibrosis. Obviously, it would need to be validated, but could represent a step towards the Holy Grail of Hepatology.

Key Words: Hepatitis C metabolomics; Fibrosis; Non invasive markers; Metavir

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: A novel approach for identifying non-invasive biomarkers as a step towards an accurate serological tool for fibrosis staging in hepatitis C.

Citation: Dabos KJ. New markers of fibrosis in hepatitis C: A step towards the Holy Grail? *World J Hepatol* 2024; 16(2): 112-114

URL: <https://www.wjgnet.com/1948-5182/full/v16/i2/112.htm>

DOI: <https://dx.doi.org/10.4254/wjh.v16.i2.112>

INTRODUCTION

Hepatology is, relatively speaking, a newcomer amongst the medical specialities. Hepatologists have tirelessly worked towards better treatments for patients with liver disease and have achieved great goals resulting in transforming the lives of millions of people with liver disease. However, the ability to accurately estimate the amount of fibrosis in the liver without the need for a liver biopsy, which can be described as the Holy Grail of Hepatology remains unobtainable.

In contrast, one of the achievable goals in the near future is hopefully the elimination of hepatitis C[1]. Since the advent of Direct Acting Antivirals at the beginning of this century, we have been able to cure patients with hepatitis C with great efficacy. The goal of eliminating hepatitis C by 2030 is still a target the community strives towards.

Greatly reducing the numbers of patients with hepatitis C does not necessarily mean that patients with fibrosis and cirrhosis due to previous Hep C infection would not need any follow up[2]. There is still a risk of progression of their existing disease. Hepatologists would ideally like to be able to accurately predict at any point the possibility of progression of liver fibrosis in patient with hepatitis C.

There are already plenty of non invasive fibrosis assessment tests in Chronic Hepatitis C (CHC), which can be classified into physical and serological ones. The most common physical test used in the West is Transient Elastography (Fibroscan, Echosens)[3]. By measuring the liver elasticity it gives a pretty good approximation of the fibrosis stage in CHC. However, very expensive equipment is required and many resource strapped countries cannot rely on it for a comprehensive assessment of the affected population. Acoustic radiation force impulse elastography and magnetic resonance enterography (a 2D gradient recalled Echo) have also been used but are not widely available[4].

Many serological tests are available using direct and indirect biomarkers. Direct biomarkers such as Hyaluronic Acid, European Liver fibrosis panel, Procollagen II, (aspartate amino transferase) to platelets ratio and Non- alcoholic fatty liver disease fibrosis score can now be used routinely in clinical practice[5-8].

Indirect biomarkers, like red cell distribution width to platelets ratio, FIB-4 and the Forns index have been used with some success, as index tests, mainly to assess the probability of fibrosis in an individual[9-11]. Tests that combine direct and indirect biomarkers like the Fibro test and the Fibro meter index have also been used as well as combinations of serological and physical tests. The plethora of available tests indicates the lack of confidence in the Hepatology community that any one test alone can accurately predict a patient's liver fibrosis stage[4].

In the present issue of the *World Journal of Hepatology*, Ferrassi *et al*[12] examine the problem of liver fibrosis staging in CHC. They identify novel biomarkers in an effort to predict accurate fibrosis staging with the aid of the metabolome of hepatitis C patients

The authors collected plasma from 46 Patients with hepatitis C who had biopsy proven fibrosis staging, graded by the METAVIR score[12] to F1-F4 grades of fibrosis. They then used an untargeted metabolomic technique to analyse plasma metabolites, using mass spectrometry.

Their analysis found potential metabolites specific for each grade of fibrosis that showed a clustering tendency. Those metabolites' clusters were more efficient in distinguishing stage F1 and stage F4 fibrosis on the METAVIR score as between F2 and F3 stages there was an overlap.

They also analysed the accuracy of the sets of metabolites specific for each grade and found that F2 markers were less specific but the sets for the other three grades showed good sensitivity and specificity scores.

The metabolites identified were sterols, fatty acids, lipids and coenzymes. In their discussion the authors point out that markers for F1 fibrosis are linked to the viral replication of the Hep C virus. Furthermore, molecules identified as biomarkers in F2 fibrosis stage (*i.e.* ceramide) could be specifically produced in the context of CHC infection. These results make it impossible to generalise the observations to other chronic liver diseases.

CONCLUSION

Overall I think Ferrassi *et al*[11] took a different approach in identifying fibrosis biomarkers, by looking at the patients' metabolome. Their biomarkers clearly separate patients from controls. They can also separate out, patients with minimal fibrosis (F0-F1 stage) and patients with cirrhosis (F4 stage). Obviously, if these biomarkers were to be widely used, tests for all the important metabolites would need to be readily available for use in hospitals or outpatient setting and that may prove difficult and above all, costly. Nevertheless, this step could eventually lead to a metabolomic approach for novel biomarkers of Fibrosis. Obviously, it would need to be validated, but could represent a step towards the Holy Grail of Hepatology.

ACKNOWLEDGEMENTS

I am grateful to Sophia Douka, MA in Linguistics for final language polishing.

FOOTNOTES

Author contributions: Dabos KJ wrote the manuscript.

Conflict-of-interest statement: Konstantinos Dabos declares no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: United Kingdom

ORCID number: Konstantinos John Dabos [0000-0002-5082-0344](https://orcid.org/0000-0002-5082-0344).

S-Editor: Liu JH

L-Editor: A

P-Editor: Cai YX

REFERENCES

- 1 **World Health Organization.** Global Health Sector Strategy on Viral Hepatitis 2016–2021. Towards Ending Viral Hepatitis. World Health Organization, 2016. Available from: <https://apps.who.int/iris/handle/10665/246177>
- 2 **Nyberg AH,** Sadikova E, Cheetham C, Chiang KM, Shi JX, Caparosa S, Younossi ZM, Nyberg LM. Increased cancer rates in patients with chronic hepatitis C. *Liver Int* 2020; **40**: 685-693 [PMID: [31755208](https://pubmed.ncbi.nlm.nih.gov/31755208/) DOI: [10.1111/liv.14305](https://doi.org/10.1111/liv.14305)]
- 3 **Trivedi HD,** Patwardhan VR, Malik R. Chronic hepatitis C infection - Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. *Dig Liver Dis* 2019; **51**: 183-189 [PMID: [30553749](https://pubmed.ncbi.nlm.nih.gov/30553749/) DOI: [10.1016/j.dld.2018.11.016](https://doi.org/10.1016/j.dld.2018.11.016)]
- 4 **Bojanic K,** Bogojevic MS, Vukadin S, Sikora R, Ivanac G, Lucic NR, Smolic M, Tabll AA, Wu GY, Smolic R. Noninvasive Fibrosis Assessment in Chronic Hepatitis C Infection: An Update. *J Clin Transl Hepatol* 2023; **11**: 1228-1238 [PMID: [37577224](https://pubmed.ncbi.nlm.nih.gov/37577224/) DOI: [10.14218/JCTH.2022.00365](https://doi.org/10.14218/JCTH.2022.00365)]
- 5 **Rewisha E,** Salman T, Alhaddad O, Raia GA, Naguib M, Rashad S, Abdelfattah A, Metwally K, Abdelsameea E. Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients. *Clin Exp Hepatol* 2021; **7**: 320-327 [PMID: [34712835](https://pubmed.ncbi.nlm.nih.gov/34712835/) DOI: [10.5114/ceh.2021.109293](https://doi.org/10.5114/ceh.2021.109293)]
- 6 **Omran D,** Yosry A, Darweesh SK, Nabeel MM, El-Beshlawey M, Saif S, Fared A, Hassany M, Zayed RA. Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naïve chronic HCV patients. *Clin Exp Med* 2018; **18**: 45-50 [PMID: [28567544](https://pubmed.ncbi.nlm.nih.gov/28567544/) DOI: [10.1007/s10238-017-0463-4](https://doi.org/10.1007/s10238-017-0463-4)]
- 7 **Daniels SJ,** Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, Karsdal MA, Grove JI, Neil Guha I, Kawaguchi T, Torimura T, McLeod D, Akiba J, Kaye P, de Boer B, Aithal GP, Adams LA, George J. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. *Hepatology* 2019; **69**: 1075-1086 [PMID: [30014517](https://pubmed.ncbi.nlm.nih.gov/30014517/) DOI: [10.1002/hep.30163](https://doi.org/10.1002/hep.30163)]
- 8 **Elmdams MR,** Gad SAB, Gawish MSF. A Novel Noninvasive Index for Assessment of Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis C Virus Infection. *The Egypt J Hosp Med* 2021; **82**: 156-163 [DOI: [10.12816/ehjhm.2021.139649](https://doi.org/10.12816/ehjhm.2021.139649)]
- 9 **Sterling RK,** Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006; **43**: 1317-1325 [PMID: [16729309](https://pubmed.ncbi.nlm.nih.gov/16729309/) DOI: [10.1002/hep.21178](https://doi.org/10.1002/hep.21178)]
- 10 **Forns X,** Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. *Hepatology* 2002; **36**: 986-992 [PMID: [12297848](https://pubmed.ncbi.nlm.nih.gov/12297848/) DOI: [10.1053/jhep.2002.36128](https://doi.org/10.1053/jhep.2002.36128)]
- 11 **Ferrasi AC,** Lima SVG, Galvani AF, Delafiori J, Dias-Audibert FL, Catharino RR, Silva GF, Praxedes RR, Santos DB, Almeida DTM, Lima EO. Metabolomics in chronic hepatitis C: Decoding fibrosis grading and underlying pathways. *World J Hepatol* 2023; **15**: 1237-1249 [PMID: [38075010](https://pubmed.ncbi.nlm.nih.gov/38075010/) DOI: [10.4254/wjh.v15.i11.1237](https://doi.org/10.4254/wjh.v15.i11.1237)]
- 12 **Bedossa P,** Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* 1996; **24**: 289-293 [PMID: [8690394](https://pubmed.ncbi.nlm.nih.gov/8690394/) DOI: [10.1002/hep.510240201](https://doi.org/10.1002/hep.510240201)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

